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Methods Appendix
Background: Streptococcus pneumoniae causes a considerable amount of 
morbidity and mortality in children <5. However, pneumococcal conjugate 
vaccines (PCVs) can prevent much of this burden. Until recently, PCVs 
were mostly available only in developed countries using a variety of dosing 
schedules. As more lower income countries make decisions to introduce 
PCV into their national immunization programs, an optimal schedule with 
which to administer PCV has become a key policy question.
Methods: We performed a systematic review of English literature pub-
lished from 1994 to 2010 on the effects of PCV dosing schedules on immu-
nogenicity, nasopharyngeal carriage, invasive pneumococcal disease and 
pneumonia. Data were independently double abstracted and cleaned for 
analysis. Descriptive analyses were performed.
Results: We identified 12,980 citations from the literature search (12,976) 
and secondary means (44). Double review of titles and abstracts yielded 
769 articles that underwent full data abstraction. Of these, 350 were further 
analyzed and are presented in separate reports in this supplement.
Conclusions: This article presents the methods utilized in our systematic review. 
Because of the heterogenity of the study methods of the reports identified by this 
review, we did not conduct formal meta-analyses. However, these methods allow 
us to present a full landscape of the literature on PCV dosing schedules.
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Pneumococcal conjugate vaccines (PCVs) are being intro-duced into the routine immunization schedules of many 
countries, including those of developing countries. This unprec-
edented roll-out of vaccine is motivated by the recognized high 
burden of pneumococcal morbidity and mortality in young 
children. Annually, pneumococcus is estimated to cause more 
than 500,000 deaths and 14.5 million episodes of pneumonia in 
children under 5 years of age worldwide.1,2 Until recently, PCVs 
were mostly available only in developed countries because of the 
high financial cost of the vaccine. Although originally licensed 
on a three primary dose regimen plus one booster (3+1), PCVs 
have now been licensed for use on a variety of dosing sched-
ules.3–5 In addition, the World Health Organization initially rec-
ommended PCV on a schedule of 3 primary doses without a 
booster, the schedule commonly used in lower income countries.6 
As a greater number of lower income countries make decisions 
to introduce PCV into their national immunization programs, 
an optimal schedule at which to administer PCV has become a 
key policy question. We conducted a systematic review of the 
literature on PCV dosing schedules. This article describes the 
methods used to review and analyze the data from this project. 
The results of the impact of PCV dosing schedules on immu-
nogenicity, invasive pneumococccal disease (IPD), pneumonia, 
nasopharyngeal (NP) colonization and indirect effects are the 
subject of separate  publications.7–11
METHODS
The methods and analyses for this study were developed by 
the core team of study investigators with ad hoc input from relevant 
experts in the pneumococcal field. The methods used in this review 
have been modeled from similar systematic reviews of this nature.
Literature Search Strategy
We performed a systematic literature review to identify 
all available data between January 1994 and September 2010 
from published and selected unpublished sources on the immu-
nogenicity and direct and indirect effects on NP carriage, IPD 
and pneumonia of various PCV schedules for healthy children as 
well as children with underlying medical conditions (eg, sickle 
cell disease and HIV). We reviewed all data from clinical tri-
als (both randomized controlled trials and other designs), other 
clinical studies (eg, observational studies) and surveillance data-
base analyses performed in the setting of PCV use. Only studies 
published in the English language were considered for review 
because of the low likelihood that such studies had been pub-
lished in non-English journals.
Specific search terms and choice of databases were devel-
oped with the advice of a professional librarian from Johns Hopkins 
University and used to identify articles (Table 1). To be identified in 
the search, each article had to include a minimum of one “narrow 
vaccine term” and one “pneumococcal term.” Terms were listed as 
Medical Subject Headings (MeSH) or other categories specific to 
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  “Streptococcus pneumoniae”[mesh]
  (“Diplococcus”[all fields] AND “pneumoniae”[all fields])
  (“micrococcus”[all fields] AND “pneumoniae”[all fields])
  “Pneumococcus”[all fields]
  “pneumococcal”[all fields]
  “s. pneumoniae”[all fields]
  “pneumococci”[all fields]




  “Pneumonia, Pneumococcal”[mesh]
  “Meningitis, Pneumococcal”[mesh]
  “Meningitis, Streptococcal”[mesh]
  “Pneumococcal Infections”[mesh]
  “Streptococcal Infections”[mesh]
  “Otitis Media”[mesh]
  (“lobar”[all fields] AND “pneumonia”[all fields])
  (“Nasopharyngeal”[all fields] AND “carriage”[all fields])
  (“Nasopharyngeal”[all fields]AND “colonization”[all fields])
  (“ nasopharyngeal”[all fields] AND “colonisation”[all fields])
  (“Community acquired”[all fields] AND “pneumonia”[all fields])
  (“community acquired”[all fields] AND “pneumonias”[all fields])
  (“Bacteraemic”[all fields] AND “pneumonia”[all fields])
  (“bacteraemic”[all fields] AND “pneumonias”[all fields])
  (“Bacteremic”[all fields] AND “pneumonia”[all fields])
  (“bacteremic”[all fields] AND “pneumonias”[all fields])
  “Anti-pneumococcal”[all fields]
  “antipneumococcal”[all fields]
  (“lower respiratory tract infection”[all fields])
  (“lower respiratory tract infections”[all fields])
  (“Invasive disease”[all fields])
  (“invasive pneumococcal disease”[all fields])
  (“invasive bacterial disease”[all fields])
  (“Bacterial pneumonia”[all fields])
  (“Bacterial pneumonias”[all fields])
  (“Otitis Media”[all fields])
  (“inner ear infection”[all fields])





 ((“conjugate” OR “conjugated” OR “pneumococcal”[all fields] OR 
“streptococcal”[all fields])
 AND
 (“vaccine”[tiab] OR “vaccines”[tiab] OR “vaccination”[tiab] OR “vaccinated”[tiab] 
OR “immunization”[tiab] OR “immunisation”[tiab] OR “immunized”[tiab] OR 
“immunised”[tiab]))




 (“vaccine”[tiab] OR “vaccines”[tiab] OR “vaccination”[tiab] OR “vaccinated”[tiab] 





 “Pnu-Imune” [all fields]
 “Pnu Imune”[all fields]
 “PnuImune”[all fields]
 “pneu immune”[all fields]
 “pnu immune”[all fields]




 “PncOMPC vaccine” [Substance Name]
 “PncOMPC”[all fields]
 (“Pneumococcal”[all fields] AND “polysaccharide”[all fields] AND 
“meningococcal”[all fields] AND “outer”[all fields] AND “membrane”[all 
fields] AND “protein”[all fields] AND “complex”[all fields])












 “ 7-valent”[all fields]
 “Prevenar”[all fields]
 “Prevnar”[all fields]


























Loo et al The Pediatric Infectious Disease Journal • Volume 33, Number 1, Supplement 2, January 2014
S184 | www.pidj.com © 2013 Lippincott Williams & Wilkins




 • Biological Abstracts (BA)
 • Pascal Biomed
 • Global Health
 • BioAbst/Reports, Reviews, Meetings
 • Cochrane Library
 • Regional databases
 ○ African Index Medicus (AIM)
 ○ Western Region Index Medicus (WPRIM)
 ○ Index Medicus for Eastern Med. Region (IMEMR)
 ○ Index Medicus for South-East Asia Region (IMSEAR)
 ○ Latin America and Caribbean Health Sciences Info. 
(LILACS)
 ○ Pan-American Health Org. (PAHO)
 ○ IndiaMed (IndMed)
In addition to the electronic literature search, all abstracts 
from meetings of the International Symposium on Pneumococci 
and Pneumococcal Disease (1998–2010) and the Interscience Con-













 “23-valent pneumococcal capsular polysaccharide vaccine”[substance name]
 “pneumococcal surface protein”[all fields]
 “pneumococcal surface proteins”[all fields]
 “pneumococcal protein”[all fields]
 “pneumococcal proteins”[all fields]
 “streptococcal surface protein”[all fields]
 “streptococcal surface proteins”[all fields]
 “streptococcal protein”[all fields]
 “streptococcal proteins”[all fields]
Additional search elements:
  Additional controlled vocabulary used in EMBASE (pathogen/ 
  outcome terms):
   “streptococcus pneumonia”[EMTREE term]
   “lower respiratory tract infection”[EMTREE term]
   “bacterial pneumonia”[EMTREE term]
   “lobar pneumonia”[EMTREE term]
  “community acquired pneumonia”[EMTREE term]
  Additional controlled vocabulary in EMBASE (vaccine terms):
   “Pneumococcus vaccine”[EMTREE term]
   “Streptococcus vaccine”[EMTREE term]
   “Pneumococcus polysaccharide”[EMTREE term]
  Adjacency searching (near 5) used in:
   EMBASE
   Global Health
   Biological Abstracts
   Biological Abstracts/RRM
   Pascal BioMed
   Cochrane Library
  Animal limits used in:
   PubMed
   EMBASE
   Biological Abstracts
   Biological Abstracts/RRM
Other limits:
   English language
   Date: 1994–current
 Not needed – pneumococcal/streptococcal finds that did not yield  
 additional material:
   Pneumococcal Pneumonia
   Pneumococcal Pneumonias
   Pneumococcal Meningitis
   Pneumococcal Infection
   Pneumococcal Infections
   Pneumococcal mortality
   Pneumococcal mortalities
   Streptococcal infection
   Streptococcal infections
TABLE 1. Continued
Search Terms
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were also searched. Additional articles in 2010–2011 included after 
the end date of the electronic literature search (September 2010), 
were identified on an ad hoc basis.
Inclusion and Exclusion Criteria
We included all data published from January 1994 to Septem-
ber 2010 including any PCV schedule on one or more outcomes of 
interest (IPD, pneumonia, NP carriage, immunogenicity [antibody 
concentrations and functional antibody measures]) in children less 
than 15 years of age targeted to receive vaccine. Fifteen years of age 
was selected to allow for inclusion of data on catch-up schedules. We 
also included studies reporting indirect effects (NP colonization, IPD 
and pneumonia) of PCV on groups not targeted to receive vaccine, 
including unvaccinated children, older children and adult populations.
Data on licensed or about-to-be licensed products (eg, 
from Wyeth [now Pfizer, New York, NY] and GlaxoSmithKline, 
Philadelphia, PA) as well as products that are no longer being pur-
sued (eg, products from Merck and Aventis [now Sanofi Pasteur, 
 Swiftwater, PA]) were included. We included the latter products, 
because many attributes of dosing and relative immunogenicity 
may be generalizable across PCV products.
We excluded any studies that focused on vaccine target 
groups older than 15 years of age or that evaluated pneumococcal 
polysaccharide vaccine (PPV) in a primary series or as a single 
dose, although we included studies using PPV as a booster dose. 
We also excluded studies published before 1994 as these studies are 
likely to evaluate product formulations that differ too much from 
licensed products to provide relevant information for our study 
objectives. Studies with non-analyzable data (eg, from cross-sec-
tional studies that only report data before or after PCV introduction 
and would not allow for calculating impact), studies focusing on 
maternal doses of pneumococcal vaccine (PPV or PCV), dose rang-
ing studies and review articles were also excluded.
Data Abstraction and Cleaning
Two independent reviewers with expertise in pneumococ-
cal disease (J.D.L. and L.C.) screened the titles and abstracts of 
all references identified by the search strategy to create a master 
list of potentially relevant references for full-text review. To iden-
tify any missing relevant references, the list was then reviewed 
by senior staff members (C.G.W. and K.O.B.) and a second pass 
through the original title/abstract list was performed. Abstracts for 
all references flagged for inclusion were reviewed to determine if 
the full report was eligible to be included in the analysis. Full-text 
articles or abstracts (ie, from International Symposium on Pneu-
mococci and Pneumococcal Disease and Interscience Conference 
on Antimicrobial Agents and Chemotherapeutics) from all eligible 
references were abstracted for a predetermined set of variables and 
data recorded directly into a 2003 Microsoft Access (Microsoft 
Corporation, Redmond, WA) database. This information was used 
to generate “groups” of reports based on outcome of interest: IPD, 
pneumonia, immunogenicity and NP carriage.
A full-text review was then performed on all citations (both 
articles and conference abstracts) within each “group,” and detailed 
information from the citations was abstracted into a larger standard-
ized database (2007 Microsoft Access). All citations were indepen-
dently double abstracted for quality control. To guide abstractors 
in the review of citations, standard operating procedures and data 
collection forms with standardized variables were developed and 
reviewers were trained on abstraction methods. All abstractors par-
ticipated in weekly calls with the project team to troubleshoot issues 
and discuss progress updates or receive other relevant  information.
We defined “study families” as abstracts or articles gener-
ated from a single protocol, population, or surveillance system or 
other data collection system. For each study family, we identified 
a single “primary study” or main publication, which was identi-
fied through de-duplication of the data following the full double 
abstraction of each citation. For all outcomes, we identified “pri-
mary data” since data were sometimes found across >1 publication. 
Abstracts and articles containing supplemental data or substudies 
were considered secondary citations. All abstractions were then 
adjudicated and data cleaned to create an analyzable dataset.
Data Analysis
We summarized the data in descriptive analyses to provide 
an overview of the amount and variability of the data by schedules 
and outcomes. All analyses were conducted using SAS 9.2 and 9.3 
(SAS Institute Inc., Cary, NC). Outcome-specific inclusion criteria 
and analyses are described in each outcome-specific publication.
RESULTS
We identified 12,980 references through the literature search 
or by other means (ie, data were identified through a presentation, 
meeting or personal communication) (Fig. 1). A double review of 
titles and abstracts for relevance yielded 1456 references for abstrac-
tion of basic information. Based on abstracted information (eg, cita-
tion information, study type, outcome, PCV product and schedule), 
we identified 769 publications or abstracts, containing 827 outcomes, 
to be fully reviewed and abstracted. Of those, 39 primary studies were 
identified for inclusion for analysis on IPD, 63 on immunogenicity, 
32 on NP carriage, 45 on pneumonia and 36 on indirect effects.
The analyzed data represented all regions: 77 (37%) stud-
ies from Europe, 73 (35%) from North America, 20 (10%) from 
Africa, 16 (8%) from Asia, 16 (8%) from Oceania and 7 (3%) from 
Latin America and the Caribbean. The majority of studies (79%, 
n = 164) focused on PCV7 (Wyeth/Pfizer), 5% (n = 11) on PCV10 
(GlaxoSmithKline) and 1% (n = 3) on PCV13 (Wyeth/Pfizer); other 
formulations presented included PCV4 (Sanofi), PCV5 (Wyeth), 
PCV7 (Merck), PCV8 (Sanofi), PCV9 (Wyeth) and PCV11 
( GlaxoSmithKline). The numbers and percentages represent a total-
ity of all data analyzed across outcomes and could therefore include 
duplicated counts of individual studies that presented data on mul-
tiple outcomes. For individual studies with multiple outcomes, data 
for each outcome were treated as an individual study.
Six studies (3%) evaluated a 2+0 schedule, 40 (19%) a 2+1 
schedule, 74 (36%) a 3+0 schedule and 124 (66%) a 3+1 schedule.
CONCLUSION
The methodology used for this systematic literature review 
has allowed us to present the breadth and depth of literature con-
cerning the impact of PCV dosing schedules on immunogenicity, 
NP colonization and disease outcomes. Our review found that the 
majority of literature concentrated on immunogenicity or IPD out-
comes with a smaller proportion focusing on pneumonia or NP car-
riage, indicating a lack of evidence regarding the impact of PCV 
against these less-specific outcomes. Findings from our review 
also identified overall gaps in data from lower income settings, 
PCV10 and PCV13 and schedules using 2+1 or 3+0 regimens. 
Until recently, PCV7 was the only licensed vaccine product and 
mostly available only in higher-income countries that could afford 
to finance the vaccine on their own. Furthermore, most early evi-
dence of impact evaluated the use of a 3+1 schedule, with alterna-
tive schedules only recently being evaluated. Because of the hetero-
geneity of the study methods and results presented between studies, 
we were unable to conduct a formal meta-analysis, which might 
have allowed us to make summary comparisons of various dosing 
schedules. We were, however, able to fully describe the available 
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data for each PCV dosing schedule and provide stakeholders with 
complete knowledge regarding the impact of PCV on immuno-
genicity, carriage and disease.
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